Meredith Manning

“Yeah, so as Anish had mentioned, we're at the end of Q4, we were at over 180 million lives covered. And so we'd look at the various sources that you all probably look at MMIT to track the covered lives.”

“As Anish mentioned, since approval, we've made remarkable progress in launching VYKAT XR. Our success driving broad awareness and adoption reflects disciplined execution grounded in effectively introducing VYKAT XR to the prescriber community, individuals with PWS, their caregivers, and payers.”

“As Anish mentioned earlier, we are still in the early stages of our launch, and the feedback from both families and providers has been very encouraging. This indicates that our outreach to caregivers, individuals with PWS, physicians, centers of excellence, payers, and advocacy groups is resonating well.”